Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Metabolic basis of solute carrier transporters in treatment of type 2 diabetes mellitus

Le J., Chen Y., Yang W., Chen L., Ye J.

Narrative Review on Type 2 Diabetes, published in Acta Pharm Sin B (2024) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Acta Pharm Sin B (2024)
Reported sample size
—
Source database
Europe PMC
PMID
38322335
PMCID
PMC10840401
DOI
10.1016/j.apsb.2023.09.004
Citations
16

Abstract (original English)

Solute carriers (SLCs) constitute the largest superfamily of membrane transporter proteins. These transporters, present in various SLC families, play a vital role in energy metabolism by facilitating the transport of diverse substances, including glucose, fatty acids, amino acids, nucleotides, and ions. They actively participate in the regulation of glucose metabolism at various steps, such as glucose uptake ( e . g ., SLC2A4/GLUT4), glucose reabsorption ( e . g ., SLC5A2/SGLT2), thermogenesis ( e . g ., SLC25A7/UCP-1), and ATP production ( e . g ., SLC25A4/ANT1 and SLC25A5/ANT2). The activities of these transporters contribute to the pathogenesis of type 2 diabetes mellitus (T2DM). Notably, SLC5A2 has emerged as a valid drug target for T2DM due to its role in renal glucose reabsorption, leading to groundbreaking advancements in diabetes drug discovery. Alongside SLC5A2, multiple families of SLC transporters involved in the regulation of glucose homeostasis hold potential applications for T2DM therapy. SLCs also impact drug metabolism of diabetic medicines through gene polymorphisms, such as rosiglitazone ( SLCO1B1 / OATP1B1 ) and metformin ( SLC22A1 - 3 / OCT1 - 3 and SLC47A1 , 2 / MATE1 , 2 ). By consolidating insights into the biological activities and clinical relevance of SLC transporters in T2DM, this review offers a comprehensive update on their roles in controlling gluc

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research